Amanda G. Paulovich
Fellowship, Dana Farber Cancer Institute, Medical Oncology, 2004.
Postdoctoral Fellowship, MIT-Whitehead Center for Genomic Research, Computational Biology (Dr. Eric Lander), 2003.
Residency, Massachusetts General Hospital, Internal Medicine, 2000.
M.D., University of Washington, 1998.
Ph.D., University of Washington, Genetics (Dr. Leland Hartwell), 1996.
B.S., Carnegie Mellon University, Biological Sciences, 1988.
As an oncologist, Dr. Amanda Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice "precision medicine." Out of these experiences, she became passionate about developing technologies and strategies for translation of novel diagnostics and therapeutics to enable precision medicine. Genomic data has taken us a long way towards understanding cancer biology, but we still are unable to effectively predict curative therapies for patients. It is likely that some of the missing biology lies in the cancer proteome. Thus, the inability to quantitatively measure most human proteins is a major obstacle to clinical translation of biomarkers and the development of new therapeutics. To overcome this roadblock, her laboratory at Fred Hutch has spearheaded the development of targeted proteomic assays utilizing Multiple Reaction Monitoring Mass Spectrometry (MRM-MS), which provides precise and highly specific quantification of proteins with assays that can be multiplexed, standardized, reproduced, and shared across laboratories and instrument platforms (unlike conventional immunoassay methods). Having solved the roadblock, her well-established team is now leveraging this technology platform to develop transformative tools (multiplex protein assays) that will fundamentally change biomedical research and lead to improvements in patient diagnosis and treatment by facilitating precision medicine.
American Chemical Society (ACS)
Radiation Research Society (RRS)
American Society for Mass Spectrometry (ASMS)
American Association for Cancer Research (AACR)
American Association for Clinical Chemistry (AACC)
American Society for Biochemistry and Molecular Biology (ASBMB)
American Society for Clinical Investigation (ASCI)
Human Proteome Organization (HUPO)
FHCRC/UW Cancer Consortium
FHCRC Proteomics Core Faculty Advisory Committee
Member, Editorial Board of Molecular and Cellular Proteomics
Member, Editorial Board of Clinical Chemistry
Honors and Awards
2015, Distinguished Achievement in Proteomic Sciences Award from the International Human Proteome Organization
2014, Life Science Innovation Northwest (LSINW) Women to Watch in Life Science Award
2012, Inducted to American Society for Clinical Investigation (ASCI)
2005, Roger E. Moe Award for Translational Research
2002, Damon Runyon Research Fellowship, Abbott Fellow
1992, Merck Distinguished Fellow Award
1989, HHMI Research Fellowship
1988, Carnegie Mellon Award for Outstanding Research
1987, Genetics Society of America Undergraduate Research Fellowship
1986, βββ Biological Honor Society
2010-2016, Associate Professor, Department of Medicine/Division of Oncology, University of Washington School of Medicine
2005-2010, Assistant Professor, Department of Medicine/Division of Oncology, University of Washington School of Medicine
2009-2015, Associate Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
2003-2009, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
Quantifying the human proteome.. Nature biotechnology. 34(10):1033-1034.. 2016.
Proteome profiling outperforms transcriptome profiling for co-expression based gene function prediction.. Molecular & cellular proteomics : MCP.. 2016.
Proteogenomics connects somatic mutations to signalling in breast cancer.. Nature. 534(7605):55-62.. 2016.
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.. Clinical chemistry. 62(1):48-69.. 2016.
Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.. Journal of proteome research. 15(8):2717-2728.. 2016.
Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.. Methods in molecular biology (Clifton, N.J.). 1410:223-36.. 2016.
Immobilized metal affinity chromatography coupled to multiple reaction monitoring enables reproducible quantification of phospho-signaling.. Molecular & cellular proteomics : MCP.. 2015.
Peptide immunoaffinity enrichment and targeted mass spectrometry enables multiplex, quantitative pharmacodynamic studies of phospho-signaling.. Molecular & cellular proteomics : MCP.. 2015.
Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA.. Molecular & cellular proteomics : MCP. 14(2):382-98.. 2015.
Antibody-Coupled Magnetic Beads Can Be Reused in Immuno-MRM Assays To Reduce Cost and Extend Antibody Supply.. Journal of proteome research.. 2015.
CPTAC Assay Portal: a repository of targeted proteomic assays.. Nature methods. 11(7):703-4.. 2014.
Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach.. Molecular & cellular proteomics : MCP.. 2014.
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.. Nature methods. 11(2):149-55.. 2014.
Panorama: A Targeted Proteomics Knowledge Base.. Journal of proteome research.. 2014.
Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.. Molecular & cellular proteomics : MCP.. 2014.
High-Affinity Recombinant Antibody Fragments (Fabs) Can Be Applied in Peptide Enrichment Immuno-MRM Assays.. Journal of proteome research. 13(4):2187-2196.. 2014.
The Human Salivary Proteome is Radiation Responsive.. Radiation research. 181(5):521-30.. 2014.
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.. Cancer discovery. 3(10):1108-12.. 2013.
The preference for error-free or error-prone postreplication repair in Saccharomyces cerevisiae exposed to low-dose methyl methanesulfonate is cell cycle dependent.. Molecular and cellular biology. 33(8):1515-27.. 2013.
Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma.. Molecular & cellular proteomics : MCP. 11(6):M111.013854.. 2012.